| Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm N Pemmaraju, AA Lane, KL Sweet, AS Stein, S Vasu, W Blum, DA Rizzieri, ... New England Journal of Medicine 380 (17), 1628-1637, 2019 | 347 | 2019 |
| Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors M Shanavas, U Popat, LC Michaelis, V Fauble, D McLornan, R Klisovic, ... Biology of Blood and Marrow Transplantation 22 (3), 432-440, 2016 | 165 | 2016 |
| Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population S Vasu, SF Leitman, JF Tisdale, MM Hsieh, RW Childs, AJ Barrett, ... Blood, The Journal of the American Society of Hematology 112 (5), 2092-2100, 2008 | 141 | 2008 |
| Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in oncology J Crawford, PS Becker, JO Armitage, DW Blayney, J Chavez, P Curtin, ... Journal of the National Comprehensive Cancer Network 15 (12), 1520-1541, 2017 | 136 | 2017 |
| Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission S Vasu, J Kohlschmidt, K Mrózek, AK Eisfeld, D Nicolet, LJ Sterling, ... Blood advances 2 (13), 1645-1650, 2018 | 105 | 2018 |
| None of the above: thrombotic microangiopathy beyond TTP and HUS C Masias, S Vasu, SR Cataland Blood, The Journal of the American Society of Hematology 129 (21), 2857-2863, 2017 | 95 | 2017 |
| Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for … L Luznik, MC Pasquini, B Logan, RJ Soiffer, J Wu, SM Devine, N Geller, ... Journal of Clinical Oncology 40 (4), 356, 2022 | 92 | 2022 |
| MicroRNAs activate natural killer cells through Toll-like receptor signaling S He, J Chu, LC Wu, H Mao, Y Peng, CA Alvarez-Breckenridge, T Hughes, ... Blood, The Journal of the American Society of Hematology 121 (23), 4663-4671, 2013 | 89 | 2013 |
| Decitabine enhances anti-CD33 monoclonal antibody BI 836858–mediated natural killer ADCC against AML blasts S Vasu, S He, C Cheney, B Gopalakrishnan, R Mani, G Lozanski, X Mo, ... Blood, The Journal of the American Society of Hematology 127 (23), 2879-2889, 2016 | 88 | 2016 |
| Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome R Nakamura, W Saber, MJ Martens, A Ramirez, B Scott, B Oran, E Leifer, ... Journal of clinical oncology 39 (30), 3328, 2021 | 87 | 2021 |
| NCCN guidelines insights: hematopoietic growth factors, version 1.2020: featured updates to the NCCN guidelines PS Becker, EA Griffiths, LM Alwan, K Bachiashvili, A Brown, R Cool, ... Journal of the National Comprehensive Cancer Network 18 (1), 12-22, 2020 | 85 | 2020 |
| Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome AS Kittai, DA Bond, B William, A Saad, S Penza, Y Efebera, K Larkin, ... Blood Advances 4 (19), 4648-4652, 2020 | 66 | 2020 |
| Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy S Vasu, H Wu, A Satoskar, M Puto, J Roddy, W Blum, R Klisovic, ... Bone marrow transplantation 51 (9), 1241-1244, 2016 | 64 | 2016 |
| Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia P Ranganathan, X Yu, R Santhanam, J Hofstetter, A Walker, K Walsh, ... Blood, The Journal of the American Society of Hematology 125 (17), 2689-2692, 2015 | 63 | 2015 |
| MicroRNA-29b mediates altered innate immune development in acute leukemia BL Mundy-Bosse, SD Scoville, L Chen, K McConnell, HC Mao, EH Ahmed, ... The Journal of clinical investigation 126 (12), 4404-4416, 2016 | 61 | 2016 |
| Tocilizumab for steroid refractory acute graft-versus-host disease JVF Roddy, BM Haverkos, A McBride, KM Leininger, S Jaglowski, ... Leukemia & lymphoma 57 (1), 81-85, 2016 | 56 | 2016 |
| Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD SA Wall, Q Zhao, M Yearsley, L Blower, A Agyeman, P Ranganathan, ... Blood advances 2 (20), 2619-2628, 2018 | 54 | 2018 |
| The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+ CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and … R Mani, S Goswami, B Gopalakrishnan, R Ramaswamy, R Wasmuth, ... Haematologica 103 (8), 1288, 2018 | 51 | 2018 |
| Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia AR Walker, H Wang, K Walsh, B Bhatnagar, S Vasu, R Garzon, ... Leukemia & lymphoma 57 (9), 2100-2108, 2016 | 47 | 2016 |
| Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML HM Murdock, HT Kim, N Denlinger, P Vachhani, B Hambley, BS Manning, ... Blood, The Journal of the American Society of Hematology 139 (24), 3546-3557, 2022 | 46 | 2022 |
